Aisthesis Medical is excited to announce its participation in the BIO3 2024 conference's prestigious pitching event

Aisthesis Medical, an innovative healthcare technology company specializing in AI-driven early sepsis prediction, is excited to announce its participation in the BIO3 2024 conference's prestigious pitching event. Organized by the BioInnovation Greece, this event will take place during the Biomedicine, Bioinformatics & Biotechnology Forum from September 1-5, 2024, bringing together the brightest minds in bioinnovation and business.

Revolutionizing Acute Care with AI Technology

Aisthesis Medical will present its groundbreaking solution, VIOSync^TM, an AI-powered clinical decision-support system that predicts sepsis and multi-organ dysfunction up to 48 hours before onset. This early intervention technology has the potential to save lives by enabling clinicians to begin treatment sooner, improving patient outcomes, and reducing healthcare costs

“Being selected to pitch at BIO3 2024 is an incredible opportunity for us to demonstrate how VIOSync^TM can transform patient care in hospitals worldwide,” said Dr. Ioannis Gkouzionis, CEO and Co-founder of Aisthesis Medical. “We look forward to engaging with investors, partners, and thought leaders in the bioinnovation space to expand the reach of our life-saving technology.”

About BIO3 2024

BIO3 2024 is a premier event for bioinnovation showcasing advancements in biotechnology that enables opportunities for collaboration and investment. The conference provides a dynamic platform for startups and established companies to present their innovations and pitch to potential investors and partners.

Looking Ahead

Aisthesis Medical’s participation in BIO3 2024 underscores its commitment to advancing acute care through AI and predictive analytics. The company is eager to build on the momentum from the event, form strategic partnerships, and continue its mission to revolutionize the way critical conditions like sepsis are managed in hospitals around the world.